IRVING, Texas, April 24, 2018 /PRNewswire/ -- Caris Life
Sciences®, a leading innovator in molecular science
focused on fulfilling the promise of precision medicine, today
announced that Piedmont Cancer has joined Caris' Precision Oncology
Alliance™ (POA) as its 22nd member and will work with
other leading cancer centers to develop standards of care and best
practices for the use of tumor profiling, making cancer treatment
more precise and effective.
"We are pleased to welcome our colleagues at Piedmont Cancer to
the Alliance. Their extensive footprint across Georgia and commitment to improving cancer
treatment within each of the communities they serve makes Piedmont
a valuable and productive member of our Alliance," said
John Marshall, M.D., Director of the
Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer at
Georgetown Lombardi Comprehensive Cancer Center and Chief of the
Division of Hematology-Oncology at MedStar Georgetown University Hospital in Washington, D.C., and Chairman of the POA
Executive Committee.
The POA, which now consists of 22 academic, hospital and
community-based cancer institutions including five NCI-designated
Comprehensive Cancer Centers, is broadening patient access to
precision medicine tools and establishing evidence-based standards
for tumor profiling and molecular testing in oncology. The POA
utilizes Caris Molecular Intelligence®, Caris' suite of
comprehensive genomic and proteomic tumor profiling services, to
enable the practice of precision medicine by identifying therapy
options and clinical trial opportunities based on the unique
molecular characteristics of a patient's tumor. Piedmont Cancer
will also actively participate in collecting molecular data and
longitudinally tracking outcomes data for those patients that have
had their tumors profiled.
"Advancing molecular profiling and precision medicine to
identify effective treatments to ultimately improve patient care
and survival for each of our cancer patients is an important
objective of Piedmont Cancer," said Erin
Dunbar, M.D., Medical Director at the Piedmont Brain Tumor
Center. "Caris Life Sciences has built a distinguished group of
institutions to serve cancer patients through the Precision
Oncology Alliance, and we look forward to working with Caris and
the other POA members to further advance molecular profiling and
precision medicine to make it a standard of care in cancer
treatment."
Caris Molecular Intelligence assesses DNA, RNA and proteins to
reveal a molecular profile to guide more precise and individualized
treatment decisions. Based on the unique molecular characteristics
of an individual patient's cancer, the results help inform
treatment decisions by identifying therapies that have the
potential to be most effective and to rule out those that are less
likely to work.
About Caris Life Sciences
Caris Life
Sciences® is a leading innovator in molecular science
focused on fulfilling the promise of precision medicine through
quality and innovation, and the world's leading immunotherapy
diagnostic expert. Caris Molecular Intelligence®, the
company's Comprehensive Genomic Profiling Plus (CGP+) molecular
testing service, assesses DNA, RNA and proteins, including
microsatellite instability (MSI), tumor mutational burden (TMB) and
PD-L1, to reveal a molecular blueprint to guide more precise and
personalized treatment decisions. Caris' profiling services are
routinely covered by third-party payors, including CMS for Medicare
patients. The ADAPT Biotargeting System™, the company's
revolutionary and unbiased profiling platform, is currently being
utilized for drug target identification, therapeutic discovery and
development, fixed tissue-based companion diagnostics, blood-based
cancer screening and biomarker identification. Headquartered in
Irving, Texas, Caris Life Sciences
offers services throughout the U.S., Europe, Asia
and other international markets. To learn more, please visit
www.CarisLifeSciences.com.
About the Precision Oncology Alliance
The
Precision Oncology Alliance™ (POA) was established by
Caris Life Sciences® to promote the study and
appropriate use of molecular testing in the diagnosis and treatment
of cancer. The POA consists of 22 leading cancer centers, including
five NCI-Designated Cancer Centers, that have demonstrated a
commitment to precision medicine and work collaboratively toward a
common goal: to advance tumor profiling and establish standards of
care for molecular testing in oncology. The POA has produced more
than five peer-reviewed manuscripts and presented over 40 posters
at industry conferences.
About Piedmont Cancer
Piedmont is a major provider of
healthcare in Georgia, operating
11 hospitals, 21 urgent care centers, 28 Piedmont QuickCare
locations, and 527 Piedmont Clinic physician practice locations.
Piedmont Cancer provides community oncology care for patients
across the system, with 8,500 analytic cancer cases each year.
Tertiary care sites are located in Athens and Atlanta, and at the John B. Amos Cancer Center
in Columbus. For more information
contact Piedmont Cancer, 1800 Howell Mill Road, Suite 625,
Atlanta, GA. Telephone
404-425-1800.
Media Inquiries:
The Ruth Group
Kirsten Thomas / Joanna Zimmerman
kthomas@theruthgroup.com / jzimmerman@theruthgroup.com
Tel: +1-508-280-6592 / +1-646-536-7006
View original
content:http://www.prnewswire.com/news-releases/piedmont-cancer-joins-caris-life-sciences-precision-oncology-alliance-300634781.html
SOURCE Caris Life Sciences